Mechanisms of transthyretin inhibition of β-amyloid aggregation in vitro

Journal of Neuroscience

Volumn 33, Issue 50, 2013, Pages 19423-19433

  Li, Xinyi ^a   Zhang, Xin ^a   Ladiwala, Ali Reza A ^b   Du, Deguo ^c   Yadav, Jay K ^d   Tessier, Peter M ^b   Wright, Peter E ^a   Kelly, Jeffery W ^a   Buxbaum, Joel N ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^c FLORIDA ATLANTIC UNIVERSITY   (United States)

^d MAX PLANCK RESEARCH UNIT FOR ENZYMOLOGY OF PROTEIN FOLDING   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; PREALBUMIN; THYROXINE BINDING PROTEIN;

ANIMAL TISSUE; ARTICLE; ATOMIC FORCE MICROSCOPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTHERMAL TITRATION CALORIMETRY; LIGHT SCATTERING; MASS SPECTROMETRY; MOUSE; NITROGEN NUCLEAR MAGNETIC RESONANCE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN INTERACTION; PROTON NUCLEAR MAGNETIC RESONANCE; SURFACE PLASMON RESONANCE; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; EPITOPES; MICE; PREALBUMIN;

EID: 84889780860     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.2561-13.2013     Document Type: Article

References (53)

1. Ahmed M, Davis J, Aucoin D, Sato T, Ahuja S, Aimoto S, Elliott JI, Van Nostrand WE, Smith SO (2010) Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. Nat Struct Mol Biol 17:561-567. CrossRef Medline
2. Brettschneider J, Lehmensiek V, Mogel H, Pfeifle M, Dorst J, Hendrich C, Ludolph AC, Tumani H (2010) Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS). Neurosci Lett 468:23-27. CrossRef Medline
3. Brockhaus M, Ganz P, Huber W, Bohrmann B, Loetscher HR, Seelig J (2007) Thermodynamic studies on the interaction of antibodies with betaamyloid peptide. J Phys Chem B 111:1238-1243. CrossRef Medline
4. Buxbaum JN, Ye Z, Reixach N, Friske L, Levy C, Das P, Golde T, Masliah E, Roberts AR, Bartfai T (2008) Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of A beta toxicity. Proc Natl Acad Sci U S A 105:2681-2686. CrossRef Medline
5. Cascella R, Conti S, Mannini B, Li X, Buxbaum JN, Tiribilli B, Chiti F, Cecchi C (2013) Transthyretin suppresses the toxicity of oligomers formed by misfolded proteins. Biochim Biophys Acta 1832:2302-2314. CrossRef Medline
6. Castaño EM, Roher AE, Esh CL, Kokjohn TA, Beach T (2006) Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol Res 28:155-163. CrossRef Medline
7. Cavanagh J, Fairbrother WJ, Palmer AG, III, Rance M, Skelton NJ (2007) Protein NMR spectroscopy: principles and practice. Burlington, MA: Elsevier Academic.
8. Choi SH, Leight SN, Lee VMY, Li T, Wong PC, Johnson JA, Saraiva MJ, Sisodia SS (2007) Accelerated A beta deposition in APPswe/PS1 Delta E9 mice with hemizygous deletions of TTR (transthyretin). J Neurosci 27:7006-7010. CrossRef Medline
9. Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and halflife. J Neurosci 23:8844-8853. Medline
10. Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A (2006) Opposing activities protect against age-onset proteotoxicity. Science 313:1604-1610. CrossRef Medline
11. Cohen E, Paulsson JF, Blinder P, Burstyn-Cohen T, Du D, Estepa G, Adame A, Pham HM, Holzenberger M, Kelly JW, Masliah E, Dillin A (2009) Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell 139:1157-1169. CrossRef Medline
12. Costa R, Ferreira-da-Silva F, Saraiva MJ, Cardoso I (2008a) Transthyretin protects against A-beta peptide toxicity by proteolytic cleavage of the peptide: a mechanism sensitive to the Kunitz protease inhibitor. Plos One 3:e2899. CrossRef Medline
13. Costa R, Gonçalves A, Saraiva MJ, Cardoso I (2008b) Transthyretin binding to A-Beta peptide: impact on A-Beta fibrillogenesis and toxicity. FEBS Lett 582:936-942. CrossRef Medline
14. Dasilva KA, Shaw JE, McLaurin J (2010) Amyloid-beta fibrillogenesis: structural insight and therapeutic intervention. Exp Neurol 223:311-321. CrossRef Medline
15. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL (2007) A beta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282:11590-11601. CrossRef Medline
16. Du D, Murray AN, Cohen E, Kim HE, Simkovsky R, Dillin A, Kelly JW (2011) A kinetic aggregation assay allowing selective and sensitive amyloid-beta quantification in cells and tissues. Biochemistry 50:1607-1617. CrossRef Medline
17. Du J, Murphy RM (2010) Characterization of the interaction of betaamyloid with transthyretin monomers and tetramers. Biochemistry 49: 8276-8289. CrossRef Medline
18. DuJ, Cho PY, Yang DT, MurphyRM (2012) Identification of beta-amyloidbinding sites on transthyretin. Protein Eng Des Sel 25:337-345. CrossRef Medline
19. Giunta S, Valli MB, Galeazzi R, Fattoretti P, Corder EH, Galeazzi L (2005) Transthyretin inhibition of amyloid beta aggregation and toxicity. Clin Biochem 38:1112-1119. CrossRef Medline
20. Hamilton JA, Benson MD (2001) Transthyretin: a review from a structural perspective. Cell Mol Life Sci 58:1491-1521. CrossRef Medline
21. Hammarström P, Jiang X, Deechongkit S, Kelly JW (2001) Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy. Biochemistry 40:11453-11459. CrossRef Medline
22. Hammarström P, Jiang X, Hurshman AR, Powers ET, Kelly JW (2002) Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proc Natl Acad Sci U S A 99 [Suppl 4]:16427-16432. CrossRef
23. Hatterer JA, Herbert J, Hidaka C, Roose SP, Gorman JM (1993) CSF transthyretin in patients with depression. Am J Psychiatry 150:813-815. Medline
24. Hurshman Babbes AR, Powers ET, Kelly JW (2008) Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. Biochemistry 47:6969-6984. CrossRef Medline
25. Jiang X, Smith CS, Petrassi HM, Hammarström P, White JT, Sacchettini JC, Kelly JW (2001) An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. Biochemistry 40:11442-11452. CrossRef Medline
26. Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW (2012) The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol 421:185-203. Medline
27. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486-489. CrossRef Medline
28. Ladiwala AR, Dordick JS, Tessier PM (2011) Aromatic small molecules remodel toxic soluble oligomers of amyloid beta through three independent pathways. J Biol Chem 286:3209-3218. CrossRef Medline
29. Ladiwala AR, Bhattacharya M, Perchiacca JM, Cao P, Raleigh DP, Abedini A, Schmidt AM, Varkey J, Langen R, Tessier PM (2012) Rational design of potent domain antibody inhibitors of amyloid fibril assembly. Proc Natl Acad Sci U S A 109:19965-19970. CrossRef Medline
30. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL (1998) Diffusible, nonfibrillar ligands derived from A beta(1-42) are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95:6448-6453. CrossRef Medline
31. Li X, Buxbaum JN (2011) Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease? Mol Neurodegener 6:79. CrossRef Medline
32. Li X, Masliah E, Reixach N, Buxbaum JN (2011) Neuronal production of transthyretin in human and murine Alzheimer's disease: is it protective? J Neurosci 31:12483-12490. CrossRef Medline
33. Link CD (1995) Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad SciU S A 92:9368-9372. CrossRef Medline
34. Liu L, Murphy RM (2006) Kinetics of inhibition of beta-amyloid aggregation by transthyretin. Biochemistry 45:15702-15709. CrossRef Medline
35. Mazur-Kolecka B, Frackowiak J, Wiśniewski HM (1995) Apolipoproteins E3 and E4 induce, and transthyretin prevents accumulation of the Alzheimer's β-amyloid peptide in cultured vascular smooth muscle cells. Brain Res 698:217-222. CrossRef Medline
36. Monaco HL, Rizzi M, Coda A (1995) Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science 268:1039-1041. CrossRef Medline
37. Moore BD, Chakrabarty P, Levites Y, Kukar TL, Baine AM, Moroni T, Ladd TB, Das P, Dickson DW, Golde TE (2012) Overlapping profiles of Abeta peptides in the Alzheimer's disease and pathological aging brains. Alzheimer Res Ther 4:18. CrossRef Medline
38. Reixach N, Foss TR, Santelli E, Pascual J, Kelly JW, Buxbaum JN (2008) Human-murine transthyretin heterotetramers are kinetically stable and non-amyloidogenic: a lesson in the generation of transgenic models of diseases involving oligomeric proteins. J Biol Chem 283:2098-2107. CrossRef Medline
39. Riisøen H (1988) Reduced prealbumin (transthyretin) in CSF of severely demented patients with Alzheimer's disease. Acta Neurol Scand 78:455-459. CrossRef Medline
40. Sarroukh R, Cerf E, Derclaye S, Dufrêne YF, Goormaghtigh E, Ruysschaert JM, Raussens V (2011) Transformation of amyloid beta(1-40) oligomers into fibrils is characterized by a major change in secondary structure. Cell Mol Life Sci 68:1429-1438. CrossRef Medline
41. Schultz K, Nilsson K, Nielsen JE, Lindquist SG, Hjermind LE, Andersen BB, Wallin A, Nilsson C, Petersén A (2010) Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors. Eur J Neurol 17:456-460. CrossRef Medline
42. Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, Enghilde JJ, Bhasin R, Silverman J, Weisgraber KH, Coyle PK (1994) Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci U S A 91:8368-8372. CrossRef Medline
43. Schwarzman AL, Tsiper M, Wente H, Wang A, Vitek MP, Vasiliev V, Goldgaber D (2004) Amyloidogenic and anti-amyloidogenic properties of recombinant transthyretin variants. Amyloid 11:1-9. CrossRef Medline
44. Sekijima Y, Tokuda T, Kametani F, Tanaka K, Maruyama K, Ikeda S (2001) Serum transthyretin monomer in patients with familial amyloid polyneuropathy. Amyloid 8:257-262. CrossRef Medline
45. Sekijima Y, Wiseman RL, Matteson J, Hammarström P, Miller SR, Sawkar AR, Balch WE, Kelly JW (2005) The biological and chemical basis for tissue-selective amyloid disease. Cell 121:73-85. CrossRef Medline
46. Serot JM, Christmann D, Dubost T, Couturier M (1997) Cerebrospinal fluid transthyretin: aging and late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry 63:506-508. CrossRef Medline
47. Stein TD, Johnson JA (2002) Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J Neurosci 22:7380-7388. Medline
48. Stein TD, Anders NJ, DeCarli C, Chan SL, Mattson MP, Johnson JA (2004) Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APP(Sw) mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. J Neurosci 24:7707-7717. CrossRef Medline
49. Tomaselli S, Esposito V, Vangone P, van Nuland NA, Bonvin AM, Guerrini R, Tancredi T, Temussi PA, PiconeD (2006) The alpha-to-beta conformational transition of Alzheimer's Abeta-(1-42) peptide in aqueous media is reversible: a step by step conformational analysis suggests the location of beta conformation seeding. Chembiochem 7:257-267. CrossRef Medline
50. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535-539. CrossRef Medline
51. Wang SH, Liu FF, Dong XY, Sun Y (2010) Thermodynamic analysis of the molecular interactions between amyloid beta-peptide 42 and (-)-epigallocatechin-3-gallate. J Phys Chem B 114:11576-11583. CrossRef Medline
52. Wang X, Su B, Lee HG, Li X, Perry G, Smith MA, Zhu X (2009) Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J Neurosci 29:9090-9103. CrossRef Medline
53. Yang DT, Joshi G, Cho PY, Johnson JA, Murphy RM (2013) Transthyretin as both a sensor and a scavenger of beta-amyloid oligomers. Biochemistry 52:2849-2861. CrossRef Medline